68Ga-cycratide

**68Ga-cycratide** is a gallium-68–labeled cyclic peptide PET radiotracer designed for noninvasive imaging of cancers overexpressing **integrin αvβ6**, especially pancreatic ductal adenocarcinoma. It demonstrates high in vivo stability and specific binding to integrin αvβ6, enabling sensitive detection of primary pancreatic tumors and potential monitoring of therapy response. In preclinical and first-in-human studies, 68Ga-cycratide showed favorable pharmacokinetics, rapid renal clearance, low background signal in non-target organs, and a safety profile without observed adverse effects in healthy volunteers. Compared to linear integrin-targeted tracers, it offers greater serum stability and improved tumor uptake. In pilot clinical PET/CT imaging, it was comparable to [18F]FDG in identifying pancreatic lesions and post-surgery recurrence, supporting further clinical development as a cancer imaging tool[1][3][8].

Other names

Ga-68 cycratideGa68 cycratideGa 68 cycratide